EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, BRIM Biotechnology's Enterprise Value is NT$1,849.33 Mil.
BRIM Biotechnology's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-329.17 Mil. Therefore, BRIM Biotechnology's EV-to-FCF for today is -5.62.
The historical rank and industry rank for BRIM Biotechnology's EV-to-FCF or its related term are showing as below:
TPE:6885'
s EV-to-FCF Range Over the Past 10 Years
Min: -9.11 Med: -5.89 Max: -2.51
Current: -5.66
During the past 7 years, the highest EV-to-FCF of BRIM Biotechnology was -2.51. The lowest was -9.11. And the median was -5.89.
TPE:6885's EV-to-FCF is ranked worse than 100% of 330
companies
in the Biotechnology industry
Industry Median: 16.3
vs TPE:6885: -5.66
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BRIM Biotechnology's PE Ratio (TTM) for today is calculated as:
BRIM Biotechnology's share price for today is NT$21.75.
BRIM Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-3.320.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
BRIM Biotechnology EV-to-FCF Related Terms
BRIM Biotechnology EV-to-FCF Historical Data
* Premium members only.
The historical data trend for BRIM Biotechnology's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6885 vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, BRIM Biotechnology's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BRIM Biotechnology EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BRIM Biotechnology's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where BRIM Biotechnology's EV-to-FCF falls into.
BRIM Biotechnology's current Enterprise Value is NT$1,849.33 Mil.
BRIM Biotechnology's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-329.17 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BRIM Biotechnology (TPE:6885) has a EV-to-FCF of -5.62 as of Jul. 06, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on BRIM Biotechnology and its competitors. According to the industry distribution chart, BRIM Biotechnology ranks #999999 out of 330 companies in the Biotechnology industry.
Is BRIM Biotechnology's EV-to-FCF too high?
BRIM Biotechnology's current EV-to-FCF is -5.62. Based on the distribution chart, BRIM Biotechnology ranks #999999 out of 330 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BRIM Biotechnology has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BRIM Biotechnology's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BRIM Biotechnology ranks #999999 out of 330 companies for EV-to-FCF. This places BRIM Biotechnology in the lower half of its industry. The industry median EV-to-FCF is 16.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.30, based on 330 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on BRIM Biotechnology and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BRIM Biotechnology's current EV-to-FCF is -5.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BRIM Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, BRIM Biotechnology (TPE:6885) is currently considered Possible Value Trap. The stock's GF Value™ is NT$486.91, compared to a current price of NT$21.75 — trading 95.5% below its estimated fair value. The current EV-to-FCF is -5.62. BRIM Biotechnology's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For BRIM Biotechnology (TPE:6885), the current EV-to-FCF is -5.62 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BRIM Biotechnology (TPE:6885) Overvalued in 2026?
Based on GuruFocus' analysis, BRIM Biotechnology stock appears to be undervalued.
The current stock price of NT$21.75 is trading 95.5% below its estimated GF Value™ of NT$486.91.
GuruFocus considers BRIM Biotechnology to be Possible Value Trap.
Key valuation signals for TPE:6885:
EV-to-FCF: -5.62
GF Value™: NT$486.91 vs. price of NT$21.75 (95.5% below fair value)
No single metric tells the full story. See the TPE:6885 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BRIM Biotechnology Inc is engaged in the research and development of new drug translation, genetic testing services, research and development services in natural and engineering sciences, and medical laboratory services. The Group has two reportable operating segments: BRIM's main business is new drug translational development services, and Compass's main business is gene sequencing and testing technology services. It generates the majority of its revenue from the BRIM segment. Geographically, it operates in Taiwan, Japan, and the USA. It generates the majority of its revenue from Taiwan.
40GF Score
Get the complete analysis for TPE:6885
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6885 has been successfully added to your 
